AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats

Kengo Tomita, Gen Tamiya, Satoshi Ando, Naoto Kitamura, Haruna Koizumi, Shinzo Kato, Yoshinori Horie, Takehiko Kaneko, Toshifumi Azuma, Hiroshi Nagata, Hiromasa Ishii, Toshifumi Hibi

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Background: Previous work with metformin has shown that this antidiabetic agent improves nonalcoholic fatty liver in ob/ob mice. AMP-activated protein kinase (AMPK) is one of the major cellular regulators of lipid and glucose metabolism, and reportedly mediates the beneficial metabolic effects of metformin. In this study, we examined the effects of 5-aminoimidazole-4- carboxamide-1-β-D-ribofuranoside (AICAR), an AMPK activator, on an experimental model of ethanol-induced hepatic steatosis. Methods: Rats were randomly divided into three groups: (A) rats fed ethanol-containing liquid diet for six weeks; (B) rats pair-fed ethanol-containing liquid diet for six weeks, during the last three weeks of which they were subcutaneously injected with 0.5 mg AICAR/g body weight per day; (C) rats pair-fed isocaloric liquid diet without ethanol for six weeks. At the end of the six-week period, the animals were sacrificed. Serum and liver specimens were analyzed using biochemical and histologic methods, as well as real-time PCR. Results: Chronic ethanol feeding resulted in fatty liver both histologically and biochemically, whereas AICAR administration attenuated the degree of change in the liver. AICAR also decreased the hepatic sterol regulatory factor binding protein-1c (SREBP-1c) and reduced fatty acid synthase (FAS) expression; these changes led to reduced triglyceride synthesis in rat livers. Furthermore, detection of 4-hydroxy-2-nonenal (4-HNE)-protein adducts showed that the AICAR treatment also decreased the products of lipid peroxidation. Conclusion: In this preclinical rat model, AICAR, an AMPK activator, appears to protect the liver from fatty changes associated with chronic alcohol use. As such, AICAR may have a role in the treatment and prevention of alcohol-induced fatty liver.

Original languageEnglish
JournalAlcoholism: Clinical and Experimental Research
Volume29
Issue number12 SUPPL.
DOIs
Publication statusPublished - 2005 Dec

Fingerprint

Aminoimidazole Carboxamide
AMP-Activated Protein Kinases
Fatty Liver
Liver
Rats
Alcohols
Ethanol
Nutrition
Metformin
Diet
Liquids
Fatty Acid Synthases
Lipids
Sterols
Lipid Metabolism
Hypoglycemic Agents
Lipid Peroxidation
4-aminoimidazole
Real-Time Polymerase Chain Reaction
Metabolism

Keywords

  • AICAR
  • Alcohol
  • AMPK
  • Fatty Liver

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Toxicology

Cite this

AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats. / Tomita, Kengo; Tamiya, Gen; Ando, Satoshi; Kitamura, Naoto; Koizumi, Haruna; Kato, Shinzo; Horie, Yoshinori; Kaneko, Takehiko; Azuma, Toshifumi; Nagata, Hiroshi; Ishii, Hiromasa; Hibi, Toshifumi.

In: Alcoholism: Clinical and Experimental Research, Vol. 29, No. 12 SUPPL., 12.2005.

Research output: Contribution to journalArticle

Tomita, K, Tamiya, G, Ando, S, Kitamura, N, Koizumi, H, Kato, S, Horie, Y, Kaneko, T, Azuma, T, Nagata, H, Ishii, H & Hibi, T 2005, 'AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats', Alcoholism: Clinical and Experimental Research, vol. 29, no. 12 SUPPL.. https://doi.org/10.1097/01.alc.0000191126.11479.69
Tomita, Kengo ; Tamiya, Gen ; Ando, Satoshi ; Kitamura, Naoto ; Koizumi, Haruna ; Kato, Shinzo ; Horie, Yoshinori ; Kaneko, Takehiko ; Azuma, Toshifumi ; Nagata, Hiroshi ; Ishii, Hiromasa ; Hibi, Toshifumi. / AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats. In: Alcoholism: Clinical and Experimental Research. 2005 ; Vol. 29, No. 12 SUPPL.
@article{89754522e6834dce96a85a56a52265f6,
title = "AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats",
abstract = "Background: Previous work with metformin has shown that this antidiabetic agent improves nonalcoholic fatty liver in ob/ob mice. AMP-activated protein kinase (AMPK) is one of the major cellular regulators of lipid and glucose metabolism, and reportedly mediates the beneficial metabolic effects of metformin. In this study, we examined the effects of 5-aminoimidazole-4- carboxamide-1-β-D-ribofuranoside (AICAR), an AMPK activator, on an experimental model of ethanol-induced hepatic steatosis. Methods: Rats were randomly divided into three groups: (A) rats fed ethanol-containing liquid diet for six weeks; (B) rats pair-fed ethanol-containing liquid diet for six weeks, during the last three weeks of which they were subcutaneously injected with 0.5 mg AICAR/g body weight per day; (C) rats pair-fed isocaloric liquid diet without ethanol for six weeks. At the end of the six-week period, the animals were sacrificed. Serum and liver specimens were analyzed using biochemical and histologic methods, as well as real-time PCR. Results: Chronic ethanol feeding resulted in fatty liver both histologically and biochemically, whereas AICAR administration attenuated the degree of change in the liver. AICAR also decreased the hepatic sterol regulatory factor binding protein-1c (SREBP-1c) and reduced fatty acid synthase (FAS) expression; these changes led to reduced triglyceride synthesis in rat livers. Furthermore, detection of 4-hydroxy-2-nonenal (4-HNE)-protein adducts showed that the AICAR treatment also decreased the products of lipid peroxidation. Conclusion: In this preclinical rat model, AICAR, an AMPK activator, appears to protect the liver from fatty changes associated with chronic alcohol use. As such, AICAR may have a role in the treatment and prevention of alcohol-induced fatty liver.",
keywords = "AICAR, Alcohol, AMPK, Fatty Liver",
author = "Kengo Tomita and Gen Tamiya and Satoshi Ando and Naoto Kitamura and Haruna Koizumi and Shinzo Kato and Yoshinori Horie and Takehiko Kaneko and Toshifumi Azuma and Hiroshi Nagata and Hiromasa Ishii and Toshifumi Hibi",
year = "2005",
month = "12",
doi = "10.1097/01.alc.0000191126.11479.69",
language = "English",
volume = "29",
journal = "Alcoholism: Clinical and Experimental Research",
issn = "0145-6008",
publisher = "Wiley-Blackwell",
number = "12 SUPPL.",

}

TY - JOUR

T1 - AICAR, an AMPK activator, has protective effects on alcohol-induced fatty liver in rats

AU - Tomita, Kengo

AU - Tamiya, Gen

AU - Ando, Satoshi

AU - Kitamura, Naoto

AU - Koizumi, Haruna

AU - Kato, Shinzo

AU - Horie, Yoshinori

AU - Kaneko, Takehiko

AU - Azuma, Toshifumi

AU - Nagata, Hiroshi

AU - Ishii, Hiromasa

AU - Hibi, Toshifumi

PY - 2005/12

Y1 - 2005/12

N2 - Background: Previous work with metformin has shown that this antidiabetic agent improves nonalcoholic fatty liver in ob/ob mice. AMP-activated protein kinase (AMPK) is one of the major cellular regulators of lipid and glucose metabolism, and reportedly mediates the beneficial metabolic effects of metformin. In this study, we examined the effects of 5-aminoimidazole-4- carboxamide-1-β-D-ribofuranoside (AICAR), an AMPK activator, on an experimental model of ethanol-induced hepatic steatosis. Methods: Rats were randomly divided into three groups: (A) rats fed ethanol-containing liquid diet for six weeks; (B) rats pair-fed ethanol-containing liquid diet for six weeks, during the last three weeks of which they were subcutaneously injected with 0.5 mg AICAR/g body weight per day; (C) rats pair-fed isocaloric liquid diet without ethanol for six weeks. At the end of the six-week period, the animals were sacrificed. Serum and liver specimens were analyzed using biochemical and histologic methods, as well as real-time PCR. Results: Chronic ethanol feeding resulted in fatty liver both histologically and biochemically, whereas AICAR administration attenuated the degree of change in the liver. AICAR also decreased the hepatic sterol regulatory factor binding protein-1c (SREBP-1c) and reduced fatty acid synthase (FAS) expression; these changes led to reduced triglyceride synthesis in rat livers. Furthermore, detection of 4-hydroxy-2-nonenal (4-HNE)-protein adducts showed that the AICAR treatment also decreased the products of lipid peroxidation. Conclusion: In this preclinical rat model, AICAR, an AMPK activator, appears to protect the liver from fatty changes associated with chronic alcohol use. As such, AICAR may have a role in the treatment and prevention of alcohol-induced fatty liver.

AB - Background: Previous work with metformin has shown that this antidiabetic agent improves nonalcoholic fatty liver in ob/ob mice. AMP-activated protein kinase (AMPK) is one of the major cellular regulators of lipid and glucose metabolism, and reportedly mediates the beneficial metabolic effects of metformin. In this study, we examined the effects of 5-aminoimidazole-4- carboxamide-1-β-D-ribofuranoside (AICAR), an AMPK activator, on an experimental model of ethanol-induced hepatic steatosis. Methods: Rats were randomly divided into three groups: (A) rats fed ethanol-containing liquid diet for six weeks; (B) rats pair-fed ethanol-containing liquid diet for six weeks, during the last three weeks of which they were subcutaneously injected with 0.5 mg AICAR/g body weight per day; (C) rats pair-fed isocaloric liquid diet without ethanol for six weeks. At the end of the six-week period, the animals were sacrificed. Serum and liver specimens were analyzed using biochemical and histologic methods, as well as real-time PCR. Results: Chronic ethanol feeding resulted in fatty liver both histologically and biochemically, whereas AICAR administration attenuated the degree of change in the liver. AICAR also decreased the hepatic sterol regulatory factor binding protein-1c (SREBP-1c) and reduced fatty acid synthase (FAS) expression; these changes led to reduced triglyceride synthesis in rat livers. Furthermore, detection of 4-hydroxy-2-nonenal (4-HNE)-protein adducts showed that the AICAR treatment also decreased the products of lipid peroxidation. Conclusion: In this preclinical rat model, AICAR, an AMPK activator, appears to protect the liver from fatty changes associated with chronic alcohol use. As such, AICAR may have a role in the treatment and prevention of alcohol-induced fatty liver.

KW - AICAR

KW - Alcohol

KW - AMPK

KW - Fatty Liver

UR - http://www.scopus.com/inward/record.url?scp=30144445780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30144445780&partnerID=8YFLogxK

U2 - 10.1097/01.alc.0000191126.11479.69

DO - 10.1097/01.alc.0000191126.11479.69

M3 - Article

C2 - 16385230

AN - SCOPUS:30144445780

VL - 29

JO - Alcoholism: Clinical and Experimental Research

JF - Alcoholism: Clinical and Experimental Research

SN - 0145-6008

IS - 12 SUPPL.

ER -